Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tregalizumab, a humanized IgG1-type monoclonal antibody targeting CD4, selectively activates regulatory T cells (Tregs) with suppressive functions in vitro and has potential applications in researching autoimmune diseases (due to inadequate Treg activity) and allergies [1] [2] [3].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Tregalizumab, a humanized IgG1-type monoclonal antibody targeting CD4, selectively activates regulatory T cells (Tregs) with suppressive functions in vitro and has potential applications in researching autoimmune diseases (due to inadequate Treg activity) and allergies [1] [2] [3]. |
In vitro | Tregalizumab activates the suppressive function of regulatory T cells [1]. It diminishes the proliferation and cytokine secretion of isolated PBMCs stimulated with tetanus toxoid in a dose-dependent manner [1]. Tregalizumab treatment (0-30 µg/mL; 18 h) induces the downregulation of CD4 in T cells [2] and primarily instigates CD4 downregulation at sites of inflammation [2]. |
Synonyms | BT-061 |
Molecular Weight | N/A |
CAS No. | 1207446-68-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tregalizumab 1207446-68-1 BT-061 BT061 BT 061 inhibitor inhibit